Skip to main content

Table 1 Average levels of VEGF, pg/ml

From: Predictors of fibrogenesis in children with JIA: a single-center pilot study

Indicator

n

means

SD

SE

min

max

Q25

ME

Q75

Sex

Boys

25

296.43

198.12

39.62

24.56

1014.90

215.91

270.77

360.13

girls

45

368.06

419.59

62.55

23.68

2158.91

128.70

223.65

385.59

Age

10–13 y

38

385.87

453.63

73.59

67.75

2158.91

128.70

216.27

360.13

14–18 y

32

290.94

179.63

31.76

23.68

824.90

201.85

260.93

366.30

Age of JIA onset

 < 3 y

9

341.57

300.01

100.00

55.84

1042.60

177.23

218.73

440.39

3–5 y

12

227.11

213.74

61.70

23.68

824.90

111.80

170.20

277.80

6–10 y

20

304.64

229.28

51.27

24.56

1014.90

129.11

286.25

370.16

11–14 y

22

337.83

430.62

91.81

45.90

2158.91

184.97

234.55

293.98

15–18 y

7

664.11

538.89

203.68

101.52

1422.60

316.48

534.53

1422.60

Variant

oligo

25

331.97

407.48

81.50

24.56

2158.91

128.70

293.98

360.13

poly

45

348.31

329.66

49.14

23.68

1422.60

169.49

244.04

380.19

Duration

< 1 y

11

203.92

135.37

40.82

73.71

495.95

82.32

215.91

293.98

1–3 y

26

469.97

482.99

94.72

45.90

2158.91

223.65

309.10

534.53

˃ 3 y

33

288.21

251.53

43.785

23.680

1042.60

128.70

219.43

342.38

Disease activity according to JADAS-27

inactive disease

3

418.60

173.44

100.13

301.72

617.88

301.72

336.21

617.88

low

44

276.22

338.33

51.01

23.68

2158.91

115.11

193.06

306.99

moderate

19

349.67

235.99

54.14

24.56

1014.90

223.65

272.18

534.53

high

4

979.94

562.50

281.25

249.67

1422.60

537.29

1123.75

1422.60

MTX treatment

not present

18

400.71

393.11

92.66

82.32

1422.60

223.65

293.98

360.13

present

52

322.31

344.75

47.81

23.68

2158.91

147.34

222.25

366.30

Dosage of MTX, mg/m2/week

< 10

4

319.32

166.06

83.03

101.52

495.95

200.57

339.90

438.07

10–12,5

20

402.46

464.19

103.79

23.68

2158.91

208.88

260.93

369.00

12,6–15

19

301.33

284.31

65.23

24.56

1042.60

92.25

215.91

440.39

˃ 15

9

189.83

129.90

43.30

55.84

509.85

128.70

169.49

184.97

All children with JIA

 

70

342.47

356.53

42.61

23.68

2158.91

165.98

244.04

360.13

  1. Significant difference was obtained only in the following groups:
  2. Age of JIA onset
  3. (3–5 y. 15–18 y. p = 0.010; 6–10 y. 15–18 y. p = 0.022; 11–14 y. 15–18 y. p = 0.034)
  4. Duration
  5. (< 1 y. 1–3 y. p = 0.036; 1–3 y. ˃ 3 y. p = 0.049)
  6. Disease activity according to JADAS-27
  7. (inactive disease high p = 0.027; low high p = 0.001; moderate high p = 0.001)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096